Literature DB >> 18392600

[Screening: prerequisites].

M Hoffmeister1, U Haug, H Brenner.   

Abstract

Screening can be a very powerful tool for prevention or more effective treatment of diseases. However, a number of prerequisites have to be met. Only diseases with a preclinical phase, during which the disease or its precursors can be detected by a suited test, are amenable to screening. Early detection of the disease must enable either prevention or more effective management of the disease and not just prolong the "patient career". The benefits of screening must encompass potential harms, which may include, for example, complications, false positive diagnoses or over-diagnoses (i.e. the diagnosis of clinically irrelevant disease). Benefits from screening must be achieved at acceptable costs. Implementation of screening has to be based on scientific evidence and accompanied by scientific evaluation.

Entities:  

Mesh:

Year:  2008        PMID: 18392600     DOI: 10.1007/s00108-008-2127-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  12 in total

Review 1.  The revised CONSORT statement for reporting randomized trials: explanation and elaboration.

Authors:  D G Altman; K F Schulz; D Moher; M Egger; F Davidoff; D Elbourne; P C Gøtzsche; T Lang
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

Review 2.  Willingness to pay for a quality-adjusted life year: in search of a standard.

Authors:  R A Hirth; M E Chernew; E Miller; A M Fendrick; W G Weissert
Journal:  Med Decis Making       Date:  2000 Jul-Sep       Impact factor: 2.583

3.  Dissecting cost-effectiveness analysis for preventive interventions: a guide for decision makers.

Authors:  S M Teutsch; J F Murray
Journal:  Am J Manag Care       Date:  1999-03       Impact factor: 2.229

4.  The effect of fecal occult-blood screening on the incidence of colorectal cancer.

Authors:  J S Mandel; T R Church; J H Bond; F Ederer; M S Geisser; S J Mongin; D C Snover; L M Schuman
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

5.  Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis.

Authors:  Pamela M Marcus; Erik J Bergstralh; Mark H Zweig; Ann Harris; Kenneth P Offord; Robert S Fontana
Journal:  J Natl Cancer Inst       Date:  2006-06-07       Impact factor: 13.506

6.  Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.

Authors:  J S Mandel; T R Church; F Ederer; J H Bond
Journal:  J Natl Cancer Inst       Date:  1999-03-03       Impact factor: 13.506

7.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Authors:  J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

8.  Cost-saving analysis of screening colonoscopy in Germany.

Authors:  A Sieg; H Brenner
Journal:  Z Gastroenterol       Date:  2007-09       Impact factor: 2.000

9.  The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

Authors:  D G Fryback; E J Dasbach; R Klein; B E Klein; N Dorn; K Peterson; P A Martin
Journal:  Med Decis Making       Date:  1993 Apr-Jun       Impact factor: 2.583

10.  Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy.

Authors:  Eugenio Paci; Guido Miccinesi; Donella Puliti; Paola Baldazzi; Vincenzo De Lisi; Fabio Falcini; Claudia Cirilli; Stefano Ferretti; Lucia Mangone; Alba Carola Finarelli; Stefano Rosso; Nereo Segnan; Fabrizio Stracci; Adele Traina; Rosario Tumino; Manuel Zorzi
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.